{"entity":{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","aka":[],"tldr":"Genesis Molecular AI does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in the clinic pipeline.","summary":"Genesis Molecular AI, formerly Genesis Therapeutics and based in Burlingame, California, does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in its clinic-bound pipeline. It holds partnerships with Genentech, Lilly, Gilead and Incyte and rebranded in 2025. OnCo links it to AI-driven drug and target discovery. Whether physics-informed models find small molecules for targets that conventional screening missed is the question its pipeline will answer. The AI-driven drug discovery page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.genesistherapeutics.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Burlingame, CA","country":"US","companyType":"biotech","website":"https://www.genesistherapeutics.ai","investors":[],"funding":[]},"route":"/companies/genesis-molecular-ai/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"}]}}